Australia mulls adoption of EU guidance on biosimilar MAbs and other topics
This article was originally published in SRA
Executive Summary
Australia's Therapeutic Goods Administration is seeking feedback on whether or not it should adopt a number of European Union guidance documents relating to medicine development – including a guideline on biosimilar medicines containing monoclonal antibodies and another on good pharmacovigilance practices1.